US loss of exclusivity · Cardiometabolic
Repatha
Amgen
2029
US biosimilars from
2025
Today: 2026
2037
2025 worldwide sales
$3.0B
Date basis
Patent-expiry estimate
US biosimilars
No US filing found
Pharma Patent Cliff
by readouts.io
Data checked 24 October 2026 ·
Full Repatha timeline →